Table 2 Perioperative management of patients taking DOAK during elective interventions (based on [101])
From: Bleeding disorders in implant dentistry: a narrative review and a treatment guide
Duration of DOAC interruption | ||||
|---|---|---|---|---|
| Â | Dabigatran | Rivaroxaban, apixaban, edoxaban | ||
Surgical bleeding risk | Surgical bleeding risk | |||
Creatinine-clearance | Low | High | Low | High |
Recommended time of DOAC interruption before surgery | Recommended time of DOAC interruption before surgery | |||
 ≥ 80 ml min |  ≥ 24 h |  ≥ 48 h |  ≥ 24 h |  ≥ 48 h |
50–79 ml/min |  ≥ 36 h |  ≥ 72 h |  ≥ 24 h |  ≥ 48 h |
30–49 ml/min |  ≥ 48 h |  ≥ 96 h |  ≥ 24 h |  ≥ 48 h |
 < 30 ml/min | No sufficient evidence |  ≥ 36 h |  ≥ 48 h | |